|

Iparomlimab and Tuvonralimab injection Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Hebei Medical University Fourth Hospital1

Indications

  • Cancer2
  • Anti-PD-1/CTLA-4 Antibody1
  • Radiotherapy1
  • Colon Cancer1
  • Head and Neck Cancer1

Other2 trials

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.